Small molecules and antibodies have dominated the pharmaceutical
landscape for decades. However, limitations associated with therapeutic
targets deemed "undruggable" and progress in biology and
chemistry
have led to the blossoming of drug modalities and therapeutic approaches.
In 2023, a high number of 9 oligonucleotide and peptide products were
approved by the Food and Drug Administration (FDA), accounting for
16% of all drugs approved. Additionally, for the first time, a clustered
regularly interspaced short palindromic repeat (CRISPR)-Cas9 gene
therapy product was approved for the treatment of sickle cell disease.
New drug modalities possess a wide range of physicochemical properties
and structures, which complicates their analytical characterization.
Impurities are formed at each step of the oligonucleotide and peptide
solid phase synthesis and during shelf life. Longer chain lengths
lead to a higher number of closely related impurities that become
increasingly more difficult to separate from the full-length product.
Chemical modifications such as phosphorothioates (PS) result in the
presence of diastereomers, which often require orthogonal methods
for their profiling and strategies to prevent their interference with
the separation of achiral impurities. In-vitro produced mRNA and plasmid
DNA also present a variety of quality attributes that need to be determined,
such as the polyA tail length or capping efficiency. Analytical challenges
arise from the variety of drug modality physiochemical properties
and attributes, fast turnaround times, and heightened level of characterization
needed to enable data-driven decisions early in the drug development
process. This perspective provides the author’s views on the
lessons learned and strategies employed in recent years.